

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP NO. 1624**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Alenfalk, Dahlström, Hunegnaw, Karlsson, Lemurell, Lindqvist, Skjäret, and Starke**

Title: **Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity**

Serial No.: **10/596,731**

Group Art Unit: **1624**

Filed: **November 16, 2006**

Examiner: **Mark L. Berch**

Confirmation No.: **9947**

Filed by EFS Web on: **17 May 2010**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE UNDER 37 C.F.R. §1.116

In response to the Final Rejection dated May 3, 2010 in regard to the above-identified patent application, Applicants respectfully request that the application be amended as follows.

Amendment of the claims begins at page 2.

Remarks begin at page 12.